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Abstract: We aimed to identify persistent asthma phenotypes among adolescents and to evaluate
longitudinally asthma-related outcomes across phenotypes. Adolescents (13–17 years) from the
prospective, observational, and multicenter INSPIRERS studies, conducted in Portugal and Spain,
were included (n = 162). Latent class analysis was applied to demographic, environmental, and
clinical variables, collected at a baseline medical visit. Longitudinal differences in clinical variables
were assessed at a 4-month follow-up telephone contact (n = 128). Three classes/phenotypes of
persistent asthma were identified. Adolescents in class 1 (n = 87) were highly symptomatic at baseline
and presented the highest number of unscheduled healthcare visits per month and exacerbations per
month, both at baseline and follow-up. Class 2 (n = 32) was characterized by female predominance,
more frequent obesity, and uncontrolled upper/lower airways symptoms at baseline. At follow-up,
there was a significant increase in the proportion of controlled lower airway symptoms (p < 0.001).
Class 3 (n = 43) included mostly males with controlled lower airways symptoms; at follow-up, while
keeping symptom control, there was a significant increase in exacerbations/month (p = 0.015). We
have identified distinct phenotypes of persistent asthma in adolescents with different patterns in
longitudinal asthma-related outcomes, supporting the importance of profiling asthma phenotypes in
predicting disease outcomes that might inform targeted interventions and reduce future risk.
Keywords: asthma; adolescents; phenotypes; clustering; longitudinal studies; latent class analysis
1. Introduction
Asthma is one of the most common chronic diseases in children worldwide [1]. Despite
advances and changes in guidelines, there is no known treatment for asthma and the main
goal, which is to achieve disease control, remains challenging [2].
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Children with uncontrolled asthma need to use asthma medication more frequently
and are more likely to use healthcare services due to their asthma, with an increase in un-
scheduled medical visits, and hospital admissions [3–5]. Likewise, adolescents have poorer
outcomes and worse adherence due to a lack of self-management skills and insufficient
health literacy knowledge [6].
Classification and understanding of heterogeneous asthma phenotypes are the starting
point to establish individualized management plans [7] and might lead to improvements
in asthma control. Recent studies using data-driven methods provided novel insights into
meaningful and accurate asthma phenotypes based on real-life data [8–10].
However, phenotypic characterizations of adolescents with asthma are very limited,
and longitudinal studies that potentially predict long-term outcomes and personalizing
treatments are scarce. Moreover, variables collected longitudinally are of extreme impor-
tance to evaluate the stability of any derived phenotypes and to further validate them,
particularly in unselected subjects with asthma from the general population. The INSPIR-
ERS studies assessed adherence to inhaled medication among adolescents with persistent
asthma, collecting real-life data over time, with the potential to support and enable patient-
centered care and research [11,12].
Therefore, this study aims to identify persistent asthma phenotypes among adolescents
and to evaluate longitudinally asthma-related outcomes across phenotypes.
2. Materials and Methods
2.1. Study Population
We performed a secondary analysis of data from adolescents (13–17 years) enrolled
in the prospective, observational, and multicenter INSPIRERS studies, which have been
described previously [11,13]. Briefly, the INSPIRERS studies assessed adherence to asthma
inhalers among adolescents and adults with persistent asthma. During a face-to-face
baseline medical visit, patients were invited by their physicians to participate in the
study, and a convenience sample was obtained, between March 2018 and January 2020, at
30 primary and secondary care centers from Portugal and Spain.
The study protocol was approved by the Ethics Committee of all participating centers.
Before enrolment in the study, adolescents signed an assent form and a written consent
form from the parent(s) or legal guardian(s) was also obtained. In this study, we followed
the STROBE statement for reporting of observational studies [14].
2.2. Study Design and Procedures
Participants were eligible for this secondary analysis if they: (1) had a previous
medical diagnosis of persistent asthma, (2) were between 13 and 17 years old, and (3)
had an active prescription for a daily inhaled controller medication for asthma. Exclusion
criteria included a diagnosis of a chronic lung disease other than asthma or other chronic
condition with possible interference with the study aims.
Participants completed a face-to-face baseline visit (T0), where physicians reported
patients’ asthma treatment; an assessment of asthma control according to the Global
Initiative for Asthma (GINA) [2]; last reported value of percent predicted Forced Expiratory
Volume in the first second (FEV1); number of exacerbations in the past year (defined as
episodes of progressive increase in shortness of breath, cough, wheezing, and/or chest
tightness, requiring a change in maintenance therapy [15]) and of unscheduled medical
visits in the past year (consultations at primary care, specialist’s office, hospitalizations, or
emergency department).
A sociodemographic and clinical questionnaire was administered to the participants,
including height and weight, an assessment of asthma control during the previous 4 weeks
by Control of Allergic Rhinitis and Asthma Test (CARAT) questionnaire [16]. CARAT total
score (CARAT-T) is calculated by summing up the scores of all 10 questions, resulting in a
range of 0–30 points. CARAT has two domains: upper airways (CARAT-UA, range: 0–12)
and lower airways (CARAT-LA, range: 0–18). A score > 24 on CARAT-T, >8 on CARAT-UA,
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and  16 on CARAT-LA were used to define control regarding total, upper, and lower
airways symptoms, respectively [17].
Participants were interviewed by phone at 1 week (T1), 1 month (T2), and 4 months
(T3) after the face-to-face baseline visit, and their asthma control was again assessed using
CARAT. Also, exacerbations and unscheduled medical visits in the past 4 months were
recorded at T3.
2.3. Statistical Analysis
Latent class analysis (LCA) was applied to 10 variables easily collected in medical
visits both primary and secondary care, collected at T0: sex (Male/Female), asthma symp-
tom’s onset before the age of 6 years (Yes/No), presence of comorbidities (Yes/No, yes if at
least one of the following physician-reported: atopic dermatitis, rhinitis, and rhinosinusi-
tis), body mass index (BMI)   85th percentile [18] (Yes/No), exposure to environmental
tobacco smoke (ETS) (Yes/No), Pre-BD FEV1 < 80% (Yes/No), CARAT-UA and CARAT-LA
(controlled/uncontrolled),  1 exacerbation (Yes/No), and  1 unscheduled healthcare
visits (Yes/No). The optimal number of classes resulting from the variables was deter-
mined by evaluating k classes versus k-1 classes sequentially, until adding a class no longer
significantly improved the model, measured by Lo-Mendell-Rubin-adjusted likelihood
ratio test. The best model was determined by the largest entropy and the lowest Bayesian
information criteria (BIC) values [19]. Longitudinal differences in clinical variables (CARAT,
exacerbations, and unscheduled medical visits) were assessed by comparison between
baseline, T1, T2, and T3 data. The ratio of the number of exacerbations/unscheduled
healthcare visits per month was also calculated.
Categorical variables were presented as absolute frequencies and proportions. Con-
tinuous variables were presented according to their distributions: mean and standard
deviation (sd) or median (percentile 25–percentile 75: P25–P75). Group comparisons were
performed by independent t-test, Mann–Whitney, and Kruskal–Wallis tests for continuous
variables or Chi-square test for categorical variables. Multiple testing was conducted
using the Bonferroni correction when needed. Longitudinal changes in each variable were
assessed using a generalized linear model with pairwise comparisons of means, to analyze
the differences between the classes over time.
Statistical analyses were performed using IBM SPSS Statistics V.26.0 (IBM Corporation,
Armonk, NY, USA), and MPlus 6.12 (Muthén & Muthén, Los Angeles, CA, USA) was
used to conduct LCA analysis. Plots were created using GraphPad Prism V.6.0 (GraphPad
Software, La Jolla, CA, USA). The level of significance was set at 0.05.
3. Results
3.1. Characteristics of the Study Population
The sample consisted of 162 adolescents with a median (P25–P75) of 15 (14–16) years,
128 of which (78%) completed the three follow-up interviews. Baseline characteristics are
shown in Table 1.
There were no significant differences between sex and baseline characteristics, ex-
cept in: GINA asthma control, with females having significantly more proportion of
uncontrolled asthma than males (p = 0.033); and CARAT-T and CARAT-LA, with females
presenting lower scores, indicating more symptoms and poorer control (Table 1). Moreover,
most of the adolescents used a single inhaler (64%) and ICS/LABA was commonly used as
a controller asthma medication (Table 1).
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Table 1. Characteristics of adolescents at the time of enrolment (T0), according to sex (n = 162).
Characteristics Total n = 162 Male n = 83 Female n = 79 p Value 2
Age, median (P25–P75) 15 (14–16) 14 (13–16) 15 (14–16) 0.061
Age of Symptom’s onset, median (P25–P75) 6 (3–10) 5.5 (3–10) 7.0 (3–10) 0.538
BMI classification, n (%):
Underweight (<5th percentile) 3 (2) 1 (1) 2 (3) 0.537
Healthy weight (5th–85th percentile) 117 (76) 62 (80) 55 (73) 0.370
Overweight (85th–95th percentile 21 (14) 9 (11) 12 (16) 0.443
Obesity ( 95th percentile) 12 (8) 6 (8) 6 (8) 0.944
Pre-BD FEV1% predicted, mean (sd) 95.6 (16.2) 95.0 (16.8) 95.9 (15.7) 0.735
Exposure to ETS, n (%) 71 (47) 36 (43) 35 (47) 0.888
Comorbidities 1, n (%) 111 (68) 59 (64) 58 (73) 0.190
Single inhaler, n (%) 104 (64) 57 (69) 47 (59) 0.223
Inhaled medication, n (%):
ICS/LABA 114 (72) 57 (70) 57 (74) 0.608
SABA 52 (33) 22 (27) 30 (39) 0.115
ICS 45 (28) 24 (30) 21 (27) 0.743
LAMA 4 (2) 2 (2) 2 (3) 0.959
Asthma control (GINA), n (%)
Controlled 74 (46) 42 (51) 32 (41) 0.223
Partly controlled 62 (38) 33 (40) 29 (37) 0.737
Uncontrolled 25 (16) 8 (10) 17 (22) 0.033
CARAT-T, median (P25–P75) 21 (16–24) 22 (17–25) 18 (14–23) 0.010
CARAT-UA, median (P25–P75) 6 (3–8) 6 (4–8) 5 (2–7) 0.101
CARAT-LA, median (P25–P75) 15 (12–17) 16 (13–18) 14 (11–16) 0.003
Exacerbations, n (%) 91 (58) 44 (55) 47 (61) 0.443
Unscheduled healthcare visits, n (%) 39 (31) 24 (34) 15 (27) 0.395
1 Comorbidities included rhinitis, rhinosinusitis, or atopic dermatitis. 2 Independent t-test, Mann–Whitney, or Chi-square tests. In bold
are statistically significant p value at <0.05. BMI: body mass index; CARAT: Control of Allergic Rhinitis and Asthma Test; T: Total; UA:
Upper airways; LA: Lower airways; GINA: Global Initiative for Asthma, Pre-BD: Pre-bronchodilator; FEV1: Forced expiratory volume
in one second; ICS: inhaled corticosteroid; LABA: Long-acting beta-agonists; SABA: Short-acting beta agonists; LAMA: Long-acting
muscarinic antagonists.
3.2. Classes of Persistent Asthma
A three-class model was selected as the best solution for these data (Table 2), with
a significantly better fitting than a two-class model (p = 0.001), and a non-significantly
different fit from a four-class model (p = 0.195). Furthermore, the entropy of the three-class
model was 0.851, a very good overall certainty in classification, and this was the best fit for
phenotype identification as it had the lowest BIC value with minimal loss of entropy.
Adolescents in class 1 (n = 87) were equally distributed regarding sex, with most
of them having at least one comorbidity (72%). Although only 17% had FEV1 < 80%,
they were highly symptomatic at baseline, with a high proportion having unscheduled
healthcare visits and exacerbations in the past year (57% and 97%, respectively).
Class 2 (n = 32) was characterized by a predominance of females (80%), a higher
proportion of overweight/obese adolescents, and all had FEV1 above 80%. However,
this class had the highest proportion of adolescents with uncontrolled upper/lower air-
ways symptoms, with a low proportion of exacerbations (11%) and without unscheduled
healthcare visits.
Class 3 (n = 43) included mostly males, half of whom had uncontrolled upper air-
way symptoms and the majority having controlled lower airways symptoms. Similar to
class 2, in class 3 we observed a very low proportion of exacerbations and unscheduled
healthcare visits.
Int. J. Environ. Res. Public Health 2021, 18, 1015 6 of 11
Table 2. Results of latent class analysis at the time of enrollment (T0).
Variables Class 1 n = 87 Class 2 n = 32 Class 3 n = 43 1 vs. 2 p Value 1 1 vs. 3 p Value 1 2 vs. 3 p Value 1
Male 44 (50) 6 (20) 33 (76) 0.004 0.006 <0.001
BMI   85th
percentile 16 (19) 8 (25) 8 (19) 0.637 0.925 0.625
Exposure to
ETS 41 (48) 11 (39) 18 (47) 0.413 0.933 0.513
Comorbidities 63 (72) 17 (57) 32 (76) 0.797 0.379 0.647
Symptom’s
onset, before
age of 6 years
45 (52) 10 (33) 20 (50) 0.073 0.808 0.163
Pre-BD
FEV1 < 80%
11 (17) 0 (0) 8 (23) 0.041 0.517 0.022
CARAT-T,
uncontrolled 70 (81) 30 (97) 23 (56) 0.035 0.003 <0.001
CARAT-UA,
uncontrolled 71 (82) 28 (90) 26 (63) 0.292 0.023 0.011
CARAT-LA,
uncontrolled 52 (60) 31 (100) 6 (15) <0.001 <0.001 <0.001
Exacerbations,
last year 81 (97) 3 (11) 3 (8) <0.001 <0.001 0.669
Unscheduled
healthcare
visits, last year
49 (57) 0 (0) 0 (0) <0.001 <0.001 0.999
Numbers are presented as n (%). Three participants were excluded due to missing data on the main variables in the model. 1 Chi-
square test. In bold are statistically significant p-value at <0.05. BMI: body mass index; ETS: environmental tobacco smoke; Pre-BD:
pre-bronchodilator; FEV1: Forced expiratory volume in one second; CARAT: Control of Allergic Rhinitis and Asthma Test; UA: upper
airways; LA: Lower airways.
3.3. Longitudinal Assessment of Latent Classes
Of the 162 adolescents included in the baseline visit (T0), 139, 136, and 128 adolescents
respectively completed the T1, T2, and T3 follow-up phone interview. Figures 1 and 2 show
the longitudinal changes in CARAT scores (across T0, T1, T2, and T3) and in the number of
exacerbations/healthcare unscheduled per month (between T0 and T3).
Adolescents in class 1 presented an increase in CARAT scores across all time points
(Figure 1) and had the highest mean number of exacerbations and unscheduled healthcare
visits/month, both at baseline (0.25 and 0.10, respectively) and follow-up (0.44 and 0.14,
respectively) (Figure 2).
Class 2 at T3 follow-up presented a significant increase in the proportion of adoles-
cents with controlled lower airways symptoms (p < 0.001), but also a significant increase
in the number of exacerbations/month (mean difference = 0.22, p = 0.009). The num-
ber of unscheduled healthcare visits also increased, although non-significantly (mean
difference = 0.14, p = 0.10).
In class 3, although most participants kept a high proportion of lower airway symptom
control at follow-up, there was a significant increase in the mean number of exacerba-
tions/month (mean difference = 0.27, p = 0.015).
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4. Discussion
In our study, we identified three distinct phenotypes (classes) of persistent asthma
in adolescents that presented different patterns in longitudinal asthma-related outcomes.
These classes differed significantly concerning airways symptoms, exacerbations, and
the need for unscheduled healthcare visits, particularly in their longitudinal changes at
follow-up.
To identify the phenotypic heterogeneity over time in children and adolescents with
asthma, clustering techniques have been applied to broad cohorts, aiming to describe and
monitor asthma phenotypes [8–10,20]. However, the present study focused on a specific
population, adolescents with persistent asthma, and used the obtained phenotypes as a
starting point for the follow-up of these asthma phenotypes, enabling the assessment of
the trajectories of asthma control.
In our study, both at cross-sectional and longitudinal levels, the obtained classes of
adolescents with persistent asthma are clinically reasonable. Class 1 was a troublesome
exacerbation-prone asthma phenotype with a high proportion of uncontrolled disease and
more unscheduled healthcare visits, while class 3 was the mildest phenotype of adolescents
with persistent asthma, being similar to other phenotypes found in the literature among
this population [8,21–23]. Class 2, compared to the other classes, included predominantly
female adolescents, who were more frequently obese and had later-onset asthma symptoms
(>6 years-old), with a high proportion of uncontrolled disease, but with few self-reported
exacerbations/unscheduled healthcare visits. Class 2 had the lowest CARAT scores (T,
UA, and LA) at baseline, and significantly improved after four months, even with higher
CARAT LA scores than class 1. Moreover, among class 2, there was a meaningful change
in CARAT T score (improvement of 5 points), above the minimal clinically important
difference reported for CARAT questionnaire (3.5 points) [24], although it was not further
assessed in confirmatory studies, namely in adolescents. To our knowledge, this is the
first time that this phenotype is described in adolescents with persistent asthma; however,
additional studies that include more participants and more comprehensive variables are
needed to validate it.
All classes reported an increase in the number of exacerbations per month in the
follow-up, and this was significant in classes 2 and 3. A possible effect of the seasonality
of the exacerbations might be a cause of this increase; however, when interpreting these
results, one should bear in mind that a possible memory bias could explain this increase,
as participants were likely better able to remember exacerbations during the past 4 months,
compared to the first assessment at baseline (focused on the past 12 months). Also, ex-
acerbations at T0 were physician-reported and at T3 were self-reported, without clinical
validation. Specifically, class 3 was composed mainly of male adolescents that, although
keeping symptom control, reported a significant increase in exacerbations. This suggests
an underestimation of their airway symptoms that, together with the fact that adolescents
often wish to take charge of their health and/or stop the medication due to stigma [6,25],
might lead to poorer outcomes. Moreover, these findings support not only the importance
of continuously monitoring childhood asthma to reduce the impact of this disease [1] but
also that, in older children, asthma monitoring should be based both on symptomatic
patterns and in objective variable expiratory airflow limitation.
Indeed, evaluation of symptoms plays a key role in asthma diagnosis and manage-
ment [2]; however, diagnostic tests, such as lung function tests, are also important for the
diagnosis and assessment of disease. In our study, FEV1 was predominantly normal (>80%)
in classes 1 and 2, which was in line with the findings of Lee et al. [8] that described that
in some clusters/phenotypes of children and adolescents with persistent asthma, lung
function was normal, particularly in those with a lower proportion of atopy. However,
because we did not assess atopy/sensitization, a direct comparison is limited, and this
should be further studied.
Similar to our findings, it has already been described that children with uncontrolled
asthma need to use more asthma medication and are more likely to use healthcare services
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for asthma, especially unscheduled medical visits and hospital admissions [4,26]. This
points to the importance of improving knowledge on asthma control in the long-term,
particularly among adolescents. Innovative mobile health (mHealth) applications could
be a means to approach this issue, as smartphones are now widespread [27] and apps
are very appealing to inspire behavior changes, through gamification and social support,
particularly in this age range [11,28].
There are many opportunities regarding longitudinal real-life data combined with
mHealth applications, such as InspirerMundi [29] and MASK [30], which are becoming
increasingly popular among physicians, patients, and the general public. However, future
studies that combine hypothesis-independent clustering and real-life data extracted from
mHealth applications applied to asthma diagnosis and management are needed.
There are limitations in this study that should be acknowledged. First, the INSPIRERS
studies cohort is not a random sample of individuals with persistent asthma, and inclusion
was based on the presence of physician-diagnosed asthma without the need for objective
measurements, such as lung function tests, to support the diagnosis. However, our findings
must be further validated to be generalized to the greater population of adolescents with
persistent asthma. Second, the lack of data regarding atopy and viral infections should be
considered in the interpretation of our findings, as they play a major role in asthma control
and management in later childhood and adulthood [31]. Third, as with any data-driven
clustering, there are limitations in the interpretation of derived classes as being a true
set of clinically meaningful subgroups [32]; however, no clustering/group effect on the
asthma-related outcomes was observed (data not shown). Also, the choice of the variables
included in the LCA model was based on parameters being easily reported at a medical
consultation, both in primary and secondary care, and that could potentially be useful in
disease management; however, the inclusion/replacement of other variables representing
different disease domains, such as adherence to treatment, medication and inflammatory
biomarkers, should be explored. Finally, the cluster stability could not be assessed because
of the limited number of adolescents in T3; however, we aimed to monitor the baseline
latent classes concerning longitudinal asthma-related outcomes.
5. Conclusions
We have identified three distinct phenotypes of persistent asthma in adolescents
that presented different patterns in longitudinal asthma-related outcomes, supporting the
importance of profiling asthma phenotypes in predicting disease outcomes, which might
inform targeted interventions and reduce future risk.
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